OTCMKTS:TBUFF Tribute Pharmaceuticals Canada (TBUFF) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Tribute Pharmaceuticals Canada Stock (OTCMKTS:TBUFF) 30 days 90 days 365 days Advanced Chart Get TBUFF alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume50,100 shsAverage Volume71,826 shsMarket Capitalization$105.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial.Read More… Receive TBUFF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tribute Pharmaceuticals Canada and its competitors with MarketBeat's FREE daily newsletter. Email Address TBUFF Stock News HeadlinesTIFF 2024: Tragically Hip series honors beloved Canadian bandSeptember 6, 2024 | reuters.comValeo Pharma Inc. (VPHIF)May 17, 2024 | finance.yahoo.comShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.May 14, 2025 | Timothy Sykes (Ad)When her brother died, she wrote a moving tribute on a frisbee. Now, his memory is being shared from one city to the next.May 2, 2023 | yahoo.comMITSUBISHI TANABE PHARMA CANADA RECEIVES ENGAGEMENT LETTER FROM PAN-CANADIAN PHARMACEUTICAL ALLIANCE FOR RADICAVA® ORAL SUSPENSIONApril 27, 2023 | finance.yahoo.comKate Middleton pays tribute to 'incredibly sad' William as they mark St Patrick's DayMarch 21, 2023 | mirror.co.ukQueen Elizabeth II: Boats, tugs and ferries take part in Mersey tributeOctober 16, 2022 | bbc.co.ukLiz Truss pays tribute to Queen in 'passing of second Elizabethan age - speech in fullOctober 4, 2022 | mirror.co.ukSee More Headlines TBUFF Stock Analysis - Frequently Asked Questions How were Tribute Pharmaceuticals Canada's earnings last quarter? Tribute Pharmaceuticals Canada Inc. (OTCMKTS:TBUFF) issued its earnings results on Monday, March, 31st. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.02) by $0.01. The company earned $2.90 million during the quarter. How do I buy shares of Tribute Pharmaceuticals Canada? Shares of TBUFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings3/31/2014Today5/14/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorManufacturing Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:TBUFF CIKN/A Webwww.tributepharma.ca Phone+1-905-8761118FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares113,720,000Free FloatN/AMarket Cap$105.76 million OptionableNot Optionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (OTCMKTS:TBUFF) was last updated on 5/14/2025 by MarketBeat.com Staff From Our PartnersAI Boom Takes a Shocking Turn…The AI “Gold Rush” is Here… History's repeating itself — but this time, the shovels are digital. Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilver’s 332% Surge?Silver has quietly become one of the most promising investments of this cycle. Russia is now stockpiling silve...Lear Capital | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tribute Pharmaceuticals Canada Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tribute Pharmaceuticals Canada With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.